Back to mobile site

Guggenheim Starts Retension Pharmaceuticals (RTSN) at Buy

November 2, 2026 12:56 AM EST Send to a Friend
Guggenheim analyst Seamus Fernandez initiates coverage on Retension Pharmaceuticals (NASDAQ: RTSN) with a Buy rating and a price target of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login